Entera Bio (NASDAQ:ENTX) Posts Earnings Results, Misses Estimates By $0.34 EPS

Entera Bio (NASDAQ:ENTX) issued its earnings results on Friday. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.34), FiscalAI reports.

Entera Bio Stock Up 9.7%

ENTX stock traded up $0.10 during midday trading on Friday, reaching $1.13. 130,042 shares of the company’s stock traded hands, compared to its average volume of 209,793. The company has a 50-day simple moving average of $1.38 and a two-hundred day simple moving average of $1.90. Entera Bio has a 1-year low of $0.98 and a 1-year high of $3.22. The company has a market cap of $51.82 million, a price-to-earnings ratio of -4.52 and a beta of 1.83.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research report on Saturday, December 27th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research note on Monday, February 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

Insider Buying and Selling at Entera Bio

In other news, Director Geno J. Germano purchased 20,000 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $1.30 per share, with a total value of $26,000.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $52,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 69,000 shares of company stock valued at $92,530 in the last three months. Company insiders own 10.38% of the company’s stock.

Institutional Investors Weigh In On Entera Bio

Several hedge funds have recently bought and sold shares of ENTX. Superstring Capital Management LP acquired a new position in shares of Entera Bio in the fourth quarter valued at approximately $33,000. Schonfeld Strategic Advisors LLC raised its holdings in shares of Entera Bio by 5.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares during the period. Jane Street Group LLC raised its holdings in shares of Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares during the period. Renaissance Technologies LLC lifted its position in Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the period. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.